PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
R. Greil,
K. Kopeckova,
L. Arcaini,
A. Amin,
K. de Graaf,
A.-M. Jegg
Affiliations
R. Greil
1 Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT); Cancer Cluster, Salzburg, Austria
K. Kopeckova
2 Department of Oncology of the 2nd Faculty of Medicine, Charles University and Motol University Hospital, Praha, Czechia
L. Arcaini
3 Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy
